Coherus BioSciences Statistics
Share Statistics
Coherus BioSciences has 115.21M shares outstanding. The number of shares has increased by 3.46% in one year.
| Shares Outstanding | 115.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 110.59M |
| Failed to Deliver (FTD) Shares | 249.69K |
| FTD / Avg. Volume | 4.93% |
Short Selling Information
The latest short interest is 31.07M, so 26.97% of the outstanding shares have been sold short.
| Short Interest | 31.07M |
| Short % of Shares Out | 26.97% |
| Short % of Float | 28.1% |
| Short Ratio (days to cover) | 3.23 |
Valuation Ratios
The PE ratio is -1.32 and the forward PE ratio is -3.05.
| PE Ratio | -1.32 |
| Forward PE | -3.05 |
| PS Ratio | 1.22 |
| Forward PS | 0.6 |
| PB Ratio | -1.62 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | n/a |
Enterprise Valuation
Coherus BioSciences Inc. has an Enterprise Value (EV) of 691.51M.
| EV / Earnings | -2.91 |
| EV / Sales | 2.69 |
| EV / EBITDA | -3.57 |
| EV / EBIT | -3.4 |
| EV / FCF | -3.95 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of -2.49.
| Current Ratio | 1.43 |
| Quick Ratio | 1.24 |
| Debt / Equity | -2.49 |
| Total Debt / Capitalization | 167.3 |
| Cash Flow / Debt | -0.36 |
| Interest Coverage | -5.01 |
Financial Efficiency
Return on equity (ROE) is 1.23% and return on capital (ROIC) is -70.59%.
| Return on Equity (ROE) | 1.23% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -70.59% |
| Revenue Per Employee | 1.09M |
| Profits Per Employee | -1.01M |
| Employee Count | 235 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.6 |
Taxes
| Income Tax | -380.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -38.3% in the last 52 weeks. The beta is 0.69, so Coherus BioSciences 's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -38.3% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.5 |
| Relative Strength Index (RSI) | 48.85 |
| Average Volume (20 Days) | 5.06M |
Income Statement
In the last 12 months, Coherus BioSciences had revenue of 257.24M and earned -237.89M in profits. Earnings per share was -2.53.
| Revenue | 257.24M |
| Gross Profit | 94.46M |
| Operating Income | -203.20M |
| Net Income | -237.89M |
| EBITDA | -193.94M |
| EBIT | -203.20M |
| Earnings Per Share (EPS) | -2.53 |
Balance Sheet
The company has 102.89M in cash and 480.84M in debt, giving a net cash position of -377.95M.
| Cash & Cash Equivalents | 102.89M |
| Total Debt | 480.84M |
| Net Cash | -377.95M |
| Retained Earnings | -1.58B |
| Total Assets | 505.00M |
| Working Capital | 73.46M |
Cash Flow
In the last 12 months, operating cash flow was -174.88M and capital expenditures -286.00K, giving a free cash flow of -175.17M.
| Operating Cash Flow | -174.88M |
| Capital Expenditures | -286.00K |
| Free Cash Flow | -175.17M |
| FCF Per Share | -1.86 |
Margins
Gross margin is 36.72%, with operating and profit margins of -78.99% and -92.48%.
| Gross Margin | 36.72% |
| Operating Margin | -78.99% |
| Pretax Margin | -92.62% |
| Profit Margin | -92.48% |
| EBITDA Margin | -75.39% |
| EBIT Margin | -78.99% |
| FCF Margin | -68.09% |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -174.48% |
| FCF Yield | -104.86% |
Analyst Forecast
The average price target for CHRS is $7, which is 382.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 382.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.93 |
| Piotroski F-Score | 3 |